Trial reportNature medicine2023
Combined PD-1, BRAF and MEK inhibition in BRAF
Open access · hybridAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 4 pooled it
40.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 4 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.International journal of clinical oncology · 2026Pooled it
- Targeted therapy in advancedBMJ (Clinical research ed.) · 2025Pooled it
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- A comprehensive overview of the molecular features and therapeutic targets in BRAFClinical and translational medicine · 2024Pooled it
- Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.British journal of cancer · 2026Trial
- Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFCancer cell · 2025Trial
- First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.British journal of cancer · 2024Trial
- Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.Cancer discovery · 2024Trial
- SLC39-driven zinc influx orchestrates pleiotropic tumor-immune system cross-talk to establish immune suppression in colorectal cancer.Science advances · 2026Article
- Propionate promotes CD8Journal for immunotherapy of cancer · 2026Article
- Multi-omics characterization of a GPRC5AJournal of translational medicine · 2026Article
- Recent progress in clinical and molecular biological research in rectal serrated lesions.Molecular biology reports · 2026Review
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Cancer cell · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Targeting MEK1/2 inhibits mitochondrial respiration and redox homeostasis in resistant rectal cancer.Journal of bioenergetics and biomembranes · 2026Article
- Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade.Cancer discovery · 2026Article
- Complete remission following targeted therapy in BRAF V600E: mutant pulmonary lymphangitic carcinomatosis secondary to rectal cancer-a case report.Journal of medical case reports · 2026Article
- Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.The oncologist · 2026Article
- Suppression LIF with 8-Gingerol blockades colorectal cancer tumorigenesis by reversing M2-type macrophage polarization.Journal of natural medicines · 2026Article
- RAS signaling in lung adenocarcinoma is defined by lineage context and DUSP4 loss.JCI insight · 2026Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
45 authors at 4 institutions in 1 country.
Jun Tian *Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Jonathan H Chen *Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Sherry X Chao *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Karin Pelka *The Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Marios GiannakisDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9012-6982
Julian HessThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1387-4009
Kelly BurkeDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2187-0147
Vjola JorgjiMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Princy SindurakarMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Jonathan BravermanThe Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
Arnav MehtaMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Tomonori OkaMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7362-3207
Mei HuangMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
David LiebThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Maxwell SpurrellMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Jill N AllenMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Thomas A AbramsDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Jeffrey W ClarkMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9524-3600
Andrea C EnzingerDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Peter C EnzingerDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Samuel J KlempnerMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4062-0808
Nadine J McClearyDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2377-8301
Jeffrey A MeyerhardtDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
David P RyanMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Matthew B YurgelunDana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6184-9273
Katie KanterMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5778-9984
Emily E Van SeventerMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Islam BaievMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Gary ChiMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Joy JarnaginMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
William B BradfordMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4752-2677
Edmond WongMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6037-7377
Alexa G MichelMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Isobel J FetterMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6021-2713
Giulia SiravegnaMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Angelo J GemmaMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Arlene SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9736-2109
Shadmehr DemehriMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7913-2641
Rebecca LearyNovartis Institute for Biomedical Research, Cambridge, MA, USA.
Catarina D CampbellNovartis Institute for Biomedical Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3863-9841
Omer YilmazThe Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, USA.
Gad A GetzThe Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0936-0753
Aparna R ParikhMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5245-7841
Nir HacohenMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. NHACOHEN@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-2349-2656
Ryan B CorcoranMassachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. rbcorcoran@partners.org.ORCID http://orcid.org/0000-0001-8173-5778
Harvard University · USBroad Institute · USMassachusetts Institute of Technology · USNovartis (United States) · US
Funding
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3M(PQ3) The role of damaged DNA in inter-individual variation of tumor immunityR01CA208756 · NCI · BROAD INSTITUTE, INC. · PI HACOHEN, NIR · 2016 to 2020
$2.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MMalignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal CancerR00CA259511 · NCI · J. DAVID GLADSTONE INSTITUTES · PI PELKA, KARIN · 2021 to 2023
$747kMalignant Cell Engagement in Immune Circuits of Human Microsatellite-stable and Microsatellite-instable Colorectal CancerK99CA259511 · NCI · BROAD INSTITUTE, INC. · PI PELKA, KARIN · 2021 to 2021
$137kNCI NIH HHS K99 CA259511NCI NIH HHS P50 CA127003NCI NIH HHS R00 CA259511NCI NIH HHS R01 CA208756NCI NIH HHS T32 CA207021NCI NIH HHS U54 CA224068NIDDK NIH HHS P30 DK043351
Abstract
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF
Indexed as
Colorectal NeoplasmsMelanomaAntineoplastic Combined Chemotherapy ProtocolsHumansMitogen-Activated Protein Kinase KinasesMutationProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinonesBRAF protein, humanMitogen-Activated Protein Kinase KinasesProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonesPyrimidinones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.